Management of Comorbid OSA and Narcolepsy

Introduction to Comorbid OSA and Narcolepsy Management

The American Academy of Sleep Medicine recommends that patients with both obstructive sleep apnea and narcolepsy who refuse OSA treatment should be aggressively counseled on the significantly increased cardiovascular morbidity and mortality risks of untreated OSA, and initiate wake-promoting agents specifically for narcolepsy-related excessive sleepiness, while continuing to offer alternative OSA therapies at every follow-up 1

Untreated OSA is associated with significant cardiovascular morbidity, mortality, and decreased quality of life, and the natural course typically worsens over time with increasing apnea-hypopnea index and symptom severity, according to the American Academy of Sleep Medicine 2
Wake-promoting medications do not treat the underlying airway obstruction and will not reduce cardiovascular risk, hypertension, stroke, heart failure, or premature death associated with untreated OSA, as stated by the American Academy of Sleep Medicine 1
The American College of Physicians states that CPAP remains superior to all alternative treatments in reducing apnea-hypopnea index, arousal index, and improving oxygen saturation, and is the only treatment proven to normalize mortality in severe OSA 3

For mild to moderate OSA, the American Academy of Sleep Medicine recommends offering custom-made dual-block mandibular advancement devices fabricated by a qualified dental provider as first-line CPAP alternative 5
The American Academy of Sleep Medicine suggests considering positional therapy if the patient has positional OSA, but verifying efficacy with polysomnography before initiating as primary therapy 2
The American Heart Association strongly encourages weight loss for all overweight/obese patients, though this is rarely curative as monotherapy and requires follow-up sleep study after ≥10% body weight loss to reassess treatment needs 6

The American Academy of Sleep Medicine recommends providing educational, behavioral, and supportive interventions to improve potential future PAP adherence, as these are strongly recommended for all OSA patients, including those at high risk for poor adherence 5
The American Academy of Sleep Medicine advises counseling on avoidance of alcohol and sedatives before bedtime, as these can worsen OSA symptoms 2

The patient's understanding of increased risks of untreated OSA, including cardiovascular complications, metabolic disease, and mortality, should be documented, as recommended by the American Academy of Sleep Medicine 2
The superior efficacy of CPAP compared to all alternative treatments in reducing apnea-hypopnea index and improving clinical outcomes should be documented, according to the American College of Physicians 3

Regular follow-up visits should be scheduled to reassess OSA symptoms, cardiovascular status, and willingness to pursue OSA treatment, as patient preferences may change over time with education and worsening symptoms, as recommended by the American Academy of Sleep Medicine 1
Monitoring for development or progression of cardiovascular comorbidities that may motivate the patient to reconsider OSA treatment is recommended by the American Heart Association 6

The American Academy of Sleep Medicine warns against prescribing wake-promoting agents as a substitute for OSA treatment, as this creates false reassurance and does not address the life-threatening cardiovascular consequences of untreated OSA 2
The American Academy of Sleep Medicine advises against delaying offering alternative OSA treatments while waiting for the patient to "come around" to CPAP, as untreated OSA continues to cause harm; offer alternatives immediately while keeping CPAP as the preferred option 7